Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
暂无分享,去创建一个
H. Cordell | M. Allison | M. Vacca | J. Dufour | T. Roskams | R. Berlinguer-Palmini | J. Wouters | O. Govaere | M. Trost | H. Yki-Järvinen | J. Schattenberg | G. Aithal | M. Ekstedt | M. Drinnan | B. Topal | E. Bugianesi | Anetta Härtlova | S. K. Petersen | S. Francque | Q. Anstee | C. Day | S. Petta | V. Ratziu | M. Göransson | A. Daly | D. Tiniakos | R. Darlay | S. Romeo | Karine Clément | James E. Clark | Julien Peltier | Matthias Van Haele | R. Mancina | R. Younes | O. Jamialahmadi | J. Palmer | Pierre Bel Lassen | N. Martinez-Lopez | Orsolya Bilkei-Gorzo | O. Bilkei-Gorzo
[1] N. Lanthier,et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. , 2021, The New England journal of medicine.
[2] K. Clément,et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis , 2020, Science Translational Medicine.
[3] F. Tacke,et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors , 2020, Nature Reviews Gastroenterology & Hepatology.
[4] M. Allison,et al. The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. , 2020, Contemporary clinical trials.
[5] K. Clément,et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort. , 2020, Journal of hepatology.
[6] C. Ponting,et al. Resolving the fibrotic niche of human liver cirrhosis at single cell level , 2019, Nature.
[7] K. Cusi,et al. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options , 2019, JHEP reports.
[8] M. Heikenwalder,et al. From NASH to HCC: current concepts and future challenges , 2019, Nature Reviews Gastroenterology & Hepatology.
[9] S. Cockell,et al. High‐throughput sequencing identifies aetiology‐dependent differences in ductular reaction in human chronic liver disease , 2019, The Journal of pathology.
[10] Christoph H. Emmerich,et al. Triggering MSR1 promotes JNK‐mediated inflammation in IL‐4‐activated macrophages , 2019, The EMBO journal.
[11] D. Schuppan,et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , 2018, Nature Reviews Gastroenterology & Hepatology.
[12] Darjus F. Tschaharganeh,et al. TNFα sensitizes hepatocytes to FasL-induced apoptosis by NFκB-mediated Fas upregulation , 2018, Cell Death & Disease.
[13] Paul Timpson,et al. Evidence that TLR4 Is Not a Receptor for Saturated Fatty Acids but Mediates Lipid-Induced Inflammation by Reprogramming Macrophage Metabolism. , 2018, Cell metabolism.
[14] T. Luedde,et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis , 2018, Hepatology.
[15] Marju Orho-Melander,et al. Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars , 2018, Diabetes Care.
[16] J. Gugenheim,et al. CD44 is a key player in non-alcoholic steatohepatitis. , 2017, Journal of hepatology.
[17] W. Wahli,et al. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD , 2016, Gut.
[18] Yan Yue,et al. RNA sequencing and transcriptomal analysis of human monocyte to macrophage differentiation. , 2013, Gene.
[19] N. Van Rooijen,et al. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. , 2012, American journal of physiology. Gastrointestinal and liver physiology.
[20] M. Karin,et al. Saturated Fatty Acids Induce c-Src Clustering within Membrane Subdomains, Leading to JNK Activation , 2011, Cell.
[21] K. Moore,et al. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. , 2010, Gastroenterology.
[22] Michael Müller,et al. Kupffer cells promote hepatic steatosis via interleukin‐1β–dependent suppression of peroxisome proliferator‐activated receptor α activity , 2010, Hepatology.
[23] E. Brunt,et al. Nonalcoholic fatty liver disease: pathology and pathogenesis. , 2010, Annual review of pathology.
[24] B. Neuschwander‐Tetri,et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD—Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network , 2009, Hepatology.
[25] K. Moore,et al. Loss of SR-A and CD36 Activity Reduces Atherosclerotic Lesion Complexity Without Abrogating Foam Cell Formation in Hyperlipidemic Mice , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[26] W. Cawthorn,et al. TNF‐α and adipocyte biology , 2008 .
[27] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[28] K. Beier,et al. TNF‐α downregulates the peroxisome proliferator activated receptor‐α and the mRNAs encoding peroxisomal proteins in rat liver , 1997 .